Nuclear Medicine: Rosatom in Talks to Acquire Netrika Medicine
Rosatom is moving to expand its footprint in healthcare IT by negotiating the acquisition of Netrika Medicine, one of Russia’s largest medical software developers. The state corporation already owns half of the Medscan clinic network and now seeks to integrate clinics, laboratories, and digital platforms into a single ecosystem.
What’s Happening
Market sources report that Rosatom is in talks to acquire Netrika Medicine, a fast-growing high-tech company. In 2024, the company posted revenues of 1.1 billion rubles (about USD 13 million) and net profit of 407 million rubles (about USD 5 million).
Netrika already serves thousands of clinics and laboratories, processing tens of thousands of documents every day. At the Eastern Economic Forum this summer, the company announced a strategic partnership with Medscan Group to build a unified medical IT platform. The acquisition would provide Rosatom with both a technological backbone and a ready user base for new healthcare services.
Strategic Rationale
The logic is clear: Rosatom already controls half of Medscan, and now it gains the digital layer that connects clinics, laboratories, and patients. This creates strong synergy — a single system for scheduling, test result sharing, telemedicine, and data analytics accelerates service development and improves profitability.
Owning a proprietary platform reduces dependence on third-party vendors and strengthens resilience in Russia’s volatile medical software market. Just as importantly, a dedicated digital platform enhances Medscan’s investment appeal ahead of its planned IPO.
This move also reflects Rosatom’s ambition to diversify beyond nuclear energy into healthcare, building a new pillar of high-tech business.
Financial Outlook
Netrika’s financial performance stands out in a shrinking Russian medical software sector. Its strong revenue growth in 2024 and positive margins make it an attractive target. For Rosatom, acquiring the company is a logical step in expanding its medical ecosystem.
Still, integrating IT platforms with clinics takes time and requires investments in data security and certification. The medical software market remains highly sensitive to regulatory and economic shifts. Success will depend on a clear product strategy and maintaining the trust of partners and users.
Possible Scenarios
If the deal goes through, the private healthcare sector will see stronger integration. Medscan’s patients will gain more seamless services — unified login and personal accounts, easy access to their medical history, and advanced telemedicine tools.
In the baseline scenario, Rosatom builds a consolidated network: Medscan remains the physical infrastructure core, while Netrika becomes the digital platform adopted by regional clinics and laboratories. This would allow the company to scale services and prepare Medscan for a successful IPO with a transparent digital architecture.
Alternatively, Rosatom may retain Netrika as an independent product line, using it internally while gradually offering services to partners. Either way, securing control of the technology provides Rosatom with a strategic edge in healthcare.
